Bishoy M. Faltas: ctDNA is a key piece of the puzzle in building an integrated precision oncology
Bishoy M. Faltas, Chief Research Officer at the Englander Institute for Precision Medicine and an Associate Professor of Medicine and Cell and Developmental Biology at Weill Cornell Medicine, shared an article by Alexandre Pellan Cheng, et al. on X:
“ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at Weill Cornell Medicine.
Excited to share collaborative paper #2 this month. This time with the brilliant Alexandre Pellan Cheng & Dan Landau!
Highlights: Deep error-corrected WGS of cfDNA using the Ultima Genomics platform. Tumor-uninformed, ultra-sensitive detection—huge implications for detecting minimal residual disease Bladder Cancer without tumor sequencing.
Detection of mutational signatures caused by APOBEC3 mutagenic enzymes (SBS2 + SBS13) in cfDNA. These are dominant in bladder cancer and improve test performance. Detection of chemotherapy-induced signature (SBS31) in cfDNA—even without tumor present, suggesting platinum mutagenesis in non-malignant cells–> enabling monitoring of chemo-induced genotoxicity.”
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling.
Authors: Alexandre Pellan Cheng, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023